greeksoup/ stock research

Doximity, Inc.: Q3 FY2026 earnings call

What management said about Q3 FY2026, from the documents filed with the SEC on 5 February 2026: press release. Guidance figures: 1 raised, 3 new, 1 kept. The quarter’s numbers.

Key takeaways

  • Revenue rose 10% year-over-year: Revenue was $185.1 million, up from $168.6 million a year earlier, an increase of 10%. Source
  • Adjusted EBITDA rose 9%: Adjusted EBITDA was $111.4 million, up 9% from $102.0 million a year earlier. Net income was $61.6 million, down from $75.2 million. Source
  • Diluted EPS fell; non-GAAP EPS rose: Diluted EPS was $0.31 against $0.37; non-GAAP diluted EPS was $0.46 against $0.45. Non-GAAP net income was $91.1 million, a 49.3% margin against 54.2%. Source
  • AI products reached 300,000 users: AI products had over 300,000 and are described as nascent, with AI features added across the platform. Source
  • R&D expense rose 54%: Research and development expense was $34.6 million against $22.4 million a year earlier; stock-based compensation within it was $13.7 million against $4.5 million. Source
  • Operating cash flow fell 7%: Operating cash flow was $60.9 million against $65.2 million; free cash flow was $58.5 million against $63.4 million. Source
  • Repurchases rose to $196.9 million: The company repurchased $196.9 million of common stock in the quarter, against $19.3 million a year earlier; nine-month repurchases were $341.1 million. Source

“We’re proud to deliver another quarter of strong profits and record engagement,”

Jeff Tangney, co-founder and CEO of Doximity

Guidance

AreaPeriodFigureAgainst last quarter
Revenue SourceFourth quarter fiscal 2026, ending March 31, 2026$143 million to $144 millionNew
Adjusted EBITDA SourceFourth quarter fiscal 2026, ending March 31, 2026$63.5 million to $64.5 millionNew
Revenue SourceFiscal year 2026, ending March 31, 2026$642.5 million to $643.5 millionKept
Adjusted EBITDA SourceFiscal year 2026, ending March 31, 2026$355.5 million to $356.5 millionRaised from $351 million to $357 million
Share repurchases SourceNo expiration dateUp to $500 million of Class A common stockNew

What changed from last quarter

  • New guidance: Fourth-quarter revenue and adjusted EBITDA guidance given for the quarter ending March 31, 2026. Source
  • Guidance kept: Full-year revenue midpoint unchanged at $643 million; the range narrowed from $640 million to $646 million. Source
  • Guidance raised: Full-year adjusted EBITDA midpoint rose to $356 million from $354 million as the range narrowed. Source
  • New: New $500 million Class A repurchase program with no expiration date. Source

Results and growth drivers

  • Revenue rose 10% year-over-year: Revenue was $185.1 million, up from $168.6 million a year earlier, an increase of 10%. Source
  • Adjusted EBITDA rose 9%: Adjusted EBITDA was $111.4 million, up 9% from $102.0 million a year earlier. Net income was $61.6 million, down from $75.2 million. Source
  • Diluted EPS fell; non-GAAP EPS rose: Diluted EPS was $0.31 against $0.37; non-GAAP diluted EPS was $0.46 against $0.45. Non-GAAP net income was $91.1 million, a 49.3% margin against 54.2%. Source
  • Operating income declined 10%: Income from operations was $71.9 million against $79.9 million. Other income, net was $8.9 million against $9.9 million. Source
  • Full-year and fourth-quarter guidance updated: Management gave fourth-quarter guidance and updated full-year ranges for revenue and adjusted EBITDA. Source

Product and member engagement

  • Workflow products reached 720,000: Workflow products had 720,000, described as a record quarter-over-quarter jump. Source
  • Newsfeed passed 1 million prescribers: Newsfeed had more than 1 million quarterly active prescribers, according to management. Source
  • AI products reached 300,000 users: AI products had over 300,000 and are described as nascent, with AI features added across the platform. Source
  • Prior-quarter workflow and AI usage: The prior release reported 650,000 prescribers using workflow tools, with AI Scribe and DoxGPT users up over 50% in that quarter.

“In short, the addition of AI features across our platform has made us more useful than ever.”

Jeff Tangney, co-founder and CEO of Doximity

Costs and margins

  • R&D expense rose 54%: Research and development expense was $34.6 million against $22.4 million a year earlier; stock-based compensation within it was $13.7 million against $4.5 million. Source
  • Stock compensation rose to $33.5 million: Total stock-based compensation was $33.5 million against $19.4 million. General and administrative expense was $17.7 million against $13.6 million. Source
  • Adjusted EBITDA margin near prior level: Adjusted EBITDA margin was 60.2% against 60.5% for the quarter; the nine-month margin was 58.5% against 56.5%. Source

Cash flow and balance sheet

  • Operating cash flow fell 7%: Operating cash flow was $60.9 million against $65.2 million; free cash flow was $58.5 million against $63.4 million. Source
  • Receivables higher than at March: Accounts receivable were $156.6 million at December 31, 2025, against $128.4 million at March 31, 2025. Source
  • Current deferred revenue declined: Current deferred revenue was $66.3 million at December 31, 2025, against $114.3 million at March 31, 2025. Source
  • Cash and securities held at quarter end: Cash and cash equivalents were $64.8 million and marketable securities $670.3 million at December 31, 2025. Source

Capital returns and buybacks

  • Repurchases rose to $196.9 million: The company repurchased $196.9 million of common stock in the quarter, against $19.3 million a year earlier; nine-month repurchases were $341.1 million. Source
  • Program has no expiration date: The program has no expiration date and is subject to business and market conditions; purchases may be open market, privately negotiated, or under Rule 10b5-1 plans. Source
  • Diluted share count lower: Diluted weighted-average shares were 199.2 million against 202.2 million a year earlier. Source

Legal and acquisition items

  • Legal expenses excluded from non-GAAP: Legal expenses were $1.9 million in the quarter and $4.8 million for nine months; the company excludes them from non-GAAP measures. Source
  • Acquisition cash paid in nine months: Cash paid for an acquisition, net of cash acquired, was $26.5 million in the nine months ended December 31, 2025, with no payment in the quarter. Source
  • Goodwill and intangibles increased: Goodwill rose to $85.0 million and intangible assets, net, to $37.3 million, from $67.9 million and $23.1 million at March 31, 2025. Source

Coming up, as management said on 5 February 2026

  • Fourth quarter ends March 31, 2026: Guidance covers the fourth quarter ending March 31, 2026, the next period the company will report. Source

Figures management reported

FigureReported
Network members, share of U.S. physicians Sourcemore than 85% (prior release: more than 80%)

Risks management discussed

  • Regulatory: Legal matters, including the shareholder class action, generated fees that the company excludes from non-GAAP results. Source

Other quarters

Summarised with AI from the documents the company filed with the SEC. Every point is checked against the filing before it is shown: management’s own words word for word, figures against the line or table row they come from. A point that fails the check is left out. Source opens the filing at that line.